LONDON: Halma plc, a global group of life-saving technology companies, announced today it has acquired itemedical and Naslund Medical in bolt-on deals for its Healthcare Sector subsidiaries, SSG and IZI Medical respectively.
The acquisitions strengthen Halma’s position in specialist healthcare markets and align with its disciplined, long-term approach to mergers and acquisitions. Both businesses add complementary capabilities and support growth in areas driven by hospital digitalization and precision oncology.
Halma, which reported record acquisition spending of £475 million in fiscal 2026, continues to deploy capital into purpose-aligned companies in niches supported by long-term growth drivers .
Digital Patient Monitoring Enhances SSG Platform
itemedical, a Dutch provider of digital platforms that integrate real-time patient data and alarms from medical devices, supports clinical decision-making and workflow efficiency in hospitals.
The acquisition enhances SSG’s digital capabilities and expands its hospital workflow management offerings. The market is driven by increasing digitalization in healthcare systems worldwide.
Halma paid €23 million (approximately £20 million) cash consideration for itemedical on a cash- and debt-free basis, funded from existing facilities. The company reported unaudited revenue of €7.8 million (approximately £7 million) for the 12 months ending March 31, 2026.
Fiducial Marker Technology Bolsters IZI’s Radiation Oncology Portfolio
Naslund Medical, a Swedish company specializing in fiducial marker technology for targeted cancer treatment, brings its core product Gold Anchor® to IZI Medical.
The technology enables more precise tumor targeting during radiation therapy. The acquisition broadens IZI’s radiation oncology offering by adding Gold Anchor® to its existing Visicoil platform, supporting customers with a wider premium product range. Naslund also provides an established international footprint, supporting IZI’s global expansion ambitions.
The cash consideration for Naslund Medical is $45 million (approximately £34 million), on a cash- and debt-free basis, funded from existing facilities. The company’s unaudited revenue for the 12 months ending March 31, 2026, was $9.2 million (approximately £7 million).
“These acquisitions strengthen our existing companies by adding complementary capabilities in markets they know well, supporting their long-term growth while enabling improved patient outcomes,” said Marc Ronchetti, Group Chief Executive of Halma. “They operate in areas which have attractive long-term growth drivers and provide a strong platform for continued innovation and international expansion. We are pleased to welcome itemedical and Naslund Medical to Halma.”
Halma, a FTSE 100 constituent, employs more than 9,000 people in over 20 countries . The company has delivered 23 consecutive years of profit growth and 47 consecutive years of dividend growth of at least 5%.
